Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor
Melanie A. Price(The University of Sydney), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Anna DeFazio(The University of Sydney), Robert Zachariae(Aarhus University Hospital), Phyllis Butow(Royal Prince Alfred Hospital), Deepa Chauhan(The University of Sydney), Colin A. Espie(University of Oxford)
Cited by 55
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
European guideline for the diagnosis and treatment of insomnia
|Journal of Sleep Research|2017|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k